Loading…
Loading…
4132.TWO (Golden Biotechnology Corporation) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
4132.TWO does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 4132.TWO and 80,000+ other tickers.
See exactly how 4132.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 4132.TWO and 80,000+ other tickers.
Golden Biotechnology Corporation, founded in 2002 and based in New Taipei City, Taiwan, is engaged in both pharmaceutical drug discovery and the production of health-enhancing dietary supplements. The company operates internationally, serving markets in Taiwan, the United States, Japan, China, Korea, and Singapore. Its varied product line includes several health supplements: Liverty, formulated to support liver function and help alleviate fatigue. Rasle, which serves as an adjunctive therapy for autoimmune conditions. ZSAINO, a nutritional product designed to aid recovery from illness and…
No recent news available.